The Tysabri Test
This article was originally published in RPM Report
Biogen Idec and Elan's multiple sclerosis therapy Tysabri is testing a key tenet of personalized medicine: that payors will accept the argument that smaller markets require higher prices.
You may also be interested in...
Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.
Tysabri was a sure-fire blockbuster before its withdrawal. Expectations are still high now that it's been given a second chance.
Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.